Novartis files for Gleevec to treat four other cancers

04/10/2006 | Wall Street Journal, The

Novartis has applied in the U.S. and European Union to have its Gleevec, which is currently approved for treating types of leukemia and stomach cancers, also approved for use in fighting four other types of cancer. The filings are an indication of a movement under way in the drug industry in which the emphasis of cancer treatment is on genetic mutations now believed to be the cause of cancers, instead of specific body parts, The Wall Street Journal asserts.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA